
Profile
General Information
A tablet formulation of DDAVP (desmopressin acetate) has been approved for managing primary nocturnal enuresis in patients age six and over. DDAVP is a synthetic form of vasopressin that has been available in nasal spray since 1989. Vasopressin regulates water balance and urine production.
Approval Date: 1998-03-01
Company Name: Rhone Poulenc Rorer